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Dear Home Secretary
In July 2007 you asked the Advisory Council on the Misuse of Drugs to review
the classification of cannabis in the light of real public concern about the
potential mental health effects of cannabis use and, in particular, the use of
stronger strains of the drug. I have pleasure in enclosing the Council’s report.
You will note that, after a most careful scrutiny of the totality of the available
evidence, the majority of the Council’s members consider – based on its
harmfulness to individuals and society – that cannabis should remain a Class C
substance. It is judged that the harmfulness of cannabis more closely equates
with other Class C substances than with those currently classified as Class B.
In providing this advice, however, the Council wishes to emphasise that the
use of cannabis is a significant public health issue. Cannabis can
unquestionably cause harm to individuals and society. The Council therefore
advises that strategies designed to minimise its use and adverse effects must
be predominantly public health ones. Criminal justice measures – irrespective
of classification – will have only a limited effect on usage. We therefore urge
you to invite the UK’s Chief Medical Officers to develop, on behalf of the
government, a public health strategy that will meet our shared goals. Anything
less will prejudice the health of future generations.
The report also includes various research recommendations which we believe
to be important to commission. We are confident that the government, with
the Research Councils and the National Institute for Health Research, will wish
to consider these very carefully. 
In producing this report, the Council has had an extraordinary amount
of valued help from various organisations as well as from members of the
public. The Council is also very grateful to the clinicians and scientists who
gave written and oral evidence. Some of them travelled a long way to do so.
Yours sincerely
Professor Sir Michael Rawlins FMedSci
Chairman
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1. Background
1.1 The Advisory Council on the Misuse of Drugs (the Council) is
established under the Misuse of Drugs Act 1971. The Council’s current
membership is shown in Annex A. Additional experts also attended the
Council’s meetings to assist in the preparation of this report (Annex B).
1.2 The Council is required under the Misuse of Drugs Act “to keep under
review the situation in the United Kingdom with respect to drugs which
are being or appear to them likely to be misused and of which the
misuse is having or appears to them capable of having harmful effects
sufficient to constitute a social problem”.
1.3 Substances that are controlled under the Misuse of Drugs Act are
grouped, on the basis of their harmfulness, into one of three classes:
Class A (the most harmful) includes cocaine, diamorphine 
(heroin), 3,4-methylenedioxymethamphetamine (ecstasy), lysergic acid
diethylamide (LSD) and methamphetamine.
Class B (an intermediate category) includes amphetamine, 
barbiturates, codeine and methylphenidate.
Class C (less harmful) includes benzodiazepines, anabolic 
steroids, gamma-hydroxybutyrate (GHB) and cannabis.
1.4 This system of classification serves to determine the penalties for the
possession and supply of controlled substances. The current maximum
penalties are as follows:
Class A drugs: for possession – 7 years’ imprisonment and/or an
unlimited fine; for supply – life imprisonment and/or fine.
Class B drugs: for possession – 5 years’ imprisonment and/or an
unlimited fine; for supply – 14 years, imprisonment and/or fine.
Class C drugs: for possession – 2 years’ imprisonment and/or an
unlimited fine; for supply – 14 years, imprisonment and/or fine.
1.5 At the time the Misuse of Drugs Act was introduced, cannabis
preparations (apart from cannabinol and certain derivatives of
cannabinol) were placed in Class B. In 2002 the Council recommended
[1] that all cannabis products be reclassified to Class C. The Home
Secretary accepted the Council’s advice and the legislative changes
came into force on 29 January 2004.
1.6 In 2005 the Council, at the request of the Home Secretary,
reconsidered the classification of cannabis products but advised that
they should remain Class C [2]. The Home Secretary accepted the
Council’s advice.
1.7 In July 2007 the Home Secretary requested, in the light of “real public
concern about the potential mental health effects of cannabis use, in
particular the use of stronger forms of the drug, commonly known as
skunk”, that the Council re-assess the classification of cannabis. This
report represents the Council’s response to the Home Secretary’s
request.
CANNABIS: CLASSIFICATION AND PUBLIC HEALTH
3
2. Introduction
2.1 Three products of the plant Cannabis sativa (also known as hemp) are
commonly available in the UK:
• cannabis resin (hash);
• traditional herbal cannabis (marijuana); and
• sinsemilla (including skunk1).
2.1.1 Cannabis resin is prepared from the flowering and other parts of the
cannabis plant that contain many glandular trichomes. The material is
processed and compressed into hard blocks before importation into the
UK, mainly from North Africa. Users cut or crumble the resin into small
pieces and either roll it with tobacco and smoke it as a “joint” or
vaporise it in a smoking device such as a “bong”. Cannabis may also
be eaten.
2.1.2 Traditional herbal cannabis is a dried plant preparation of floral and folia
material imported from the Caribbean, Africa or Asia. Like cannabis
resin, it is either rolled with tobacco and smoked as a “joint” or
vaporised in a smoking device.
2.1.3 Sinsemilla is composed of the flowering tops of unfertilised female
cannabis plants produced by intensive indoor cultivation methods.
Although some is imported, much is now grown in the UK. As with other
forms of cannabis, it is either rolled with tobacco or vaporised in a
smoking device.
2.2 The effect of cannabis that is desired by users appears to be mediated
by the chemical component r9-tetrahydrocannabinol (THC). THC acts on
specific proteins (“cannabinoid receptors”) situated on the surface of
cells in the brain, as well as elsewhere in the body, and mimics the
action of several naturally occurring neurotransmitter substances known
as endocannabinoids.
2.3 THC, however, is only one of around 60 “cannabinoids” present in
preparations of cannabis. The pharmacological properties of most of
these are unknown. One particular cannabinoid that has attracted
recent attention is cannabidiol (CBD), which, in animals, has been
shown to have effects similar to antipsychotic drugs through an as yet
undetermined mechanism [3].
2.3.1 There are few human data on the effects of CBD but, at its meeting in
February 2008, the Council was presented with a study where it had
been given intravenously to two healthy subjects and found to reduce,
substantially, the psychomimetic actions of intravenous THC [4].
2.3.2 A recently published survey of ketamine users, who also used cannabis,
found that those who had both CBD and THC present in hair samples
exhibited a lower rating of psychosis-like symptoms than those in whom
only THC was found [5].
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1 A form of sinsemilla with a characteristic odour. It is often of high potency.
2.4 This report is based on a review of the literature, with particular
attention to material published since 2005. The Council also had the
opportunity to consider oral and written evidence (Annexes C and D
respectively) submitted by organisations and individuals with a special
interest in cannabis. The Council is particularly grateful to those who
gave evidence at its extraordinary meetings in February and April 2008.
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3. Epidemiology of cannabis use
3.1 Because it is unlawful to possess, cultivate or supply cannabis, it is
difficult to obtain precise estimates about the extent of its use.
Estimates of self-reported use in England and Wales are available from
data obtained by the British Crime Survey (BCS). The BCS is based on a
nationally representative sample of adults aged 16 to 59 living in private
households. It does not, however, include the homeless, prisoners,
residents in communal establishments such as students in halls of
residence, or problematic drug users whose lives are so busy or chaotic
that they are hardly ever at home or are unable to take part in an
interview [6]. Nor does the survey include young people under 16 years
of age. As a result, the BCS is likely to underestimate the overall use of
cannabis [6].
3.1.1 Estimates of self-reported use in Scotland are available from the
Scottish Crime and Victimisation Survey (SCVS). The SCVS has similar
limitations to the BCS [7]. In addition, in 2006 the SCVS changed the
methodology by which information is collected, from being a paper-
based survey to computer-assisted personal interviewing (CAPI). This
resulted in higher reported levels of drug misuse in 2006 compared with
previous years because it is considered that using CAPI leads to more
honest and complete responses [7]. Consequently, it is difficult to make
meaningful comparisons between the 2006 data and drug use reported
in previous years. By contrast, the BCS has used CAPI since 1994;
comparisons of use between 1994 and 2006/07 are therefore more
reliable.
3.1.2 The most recent BCS report [6] indicates that 2.6 million people aged
between 16 and 59 years in England and Wales reported using cannabis
in 2006/07; 1.5 million of these admitted use in the month preceding
the survey. These represent 8.2% and 4.8% (respectively) of the total
population of England and Wales. The most recent (2006) SCVS report
[7] indicates that 11.0% of people aged 16 to 59 years admitted using
cannabis in the past year and 6.8% in the past month.
3.1.3 The use of cannabis is predominantly among younger people (Table 1),
with prevalence rates higher for males than females. The data are also
compatible with the suggestion that, at least in the past, most young
cannabis users had stopped by their mid-thirties. The Council does not
have reliable longitudinal data to determine if this is true, or whether
the pattern of use 20 years ago was different.
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Table 1
Proportion (%) of 16 to 59 year olds reporting cannabis use ever, in the
past year, or in the past month (2006/07) [6]
Age group Use Use in the Use in the
(years) ever past year past month
16–19 31.7 20.3 11.8
20–24 46.0 31.5 12.1
25–29 46.5 13.1 8.1
30–34 41.0 8.5 4.8
35–44 29.5 4.5 2.7
45–54 18.5 2.2 1.2
55–59 12.8 1.1 0.6
3.1.4 Despite the high prevalence of cannabis use, particularly among young
people, the BCS [6] also shows that use appears to have declined by
around 20% to 25% over the past five years (Table 2) in all age groups.
Similar findings have been reported from a national survey of English
secondary schools [8].
Table 2
Proportion (%) of 16 to 59 year olds reporting cannabis use in the past
year or in the past month, between 1996 and 2006/07 [6]
16 to 59 years old 16 to 24 years old
Year Past year Past month Past year Past month
1996 9.5 5.5 26.0 16.1
1998 10.3 6.1 28.2 18.0
20002 10.5 6.4 27.0 17.4
2001/02 10.6 6.6 27.3 17.6
2002/03 10.9 6.7 26.2 16.6
2003/04 10.8 6.5 25.3 15.8
2004/05 9.7 5.6 23.6 14.1
2005/06 8.7 5.2 21.4 13.0
2006/07 8.2 4.8 20.9 12.0
3.2 Estimates of the prevalence of cannabis use among those under 16
years of age are sparse, and the data that are available are based on
small numbers. The data [9] suggest that, in 2005, the prevalence of
“ever” cannabis use among 11 to 12 year olds was around 1% to 2%,
rising to 13% in those aged 13 to 14 years. This same source also
reports that cannabis use among these age groups has fallen by about
1 percentage point since 1995, though uncertainties in measurement
mean that we cannot be sure if this represents a real reduction.
3.3 In a separate survey [10], 182 young people, aged 11 to 19 years, and
who had used cannabis and/or been involved with cannabis transactions
in recent months, were interviewed. On average they first used cannabis
when 13 years old. This provides some independent corroboration of a
trend for the early introduction of many young people to cannabis.
3.4 There has recently been an attempt, in the Netherlands, to characterise
the use of cannabis among regular users [11]. The study suggested that
users might be divided into three groups (so-called “clusters”):
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2 The fall in use over the period 2000 to 2006/07 is statistically significant. 
Cluster I: This group tended to be young males (mean age 22.7 years)
whose cannabis use was frequent and who were in pursuit of high levels
of intoxication.
Cluster II: These were older people (mean age 27.7 years) of both sexes
who sought moderate levels of intoxication. They adjusted their smoking
behaviour in response to the potency of the cannabis they were using.
Cluster III: This group consisted of mature cannabis smokers (mean age
37.5 years) whose consumption was consistently high and whose
pattern of use was little affected by the strength of the product.
3.4.1 The participants in this study were all recruited from cannabis coffee
shops in five Dutch cities. Whether they reflect the pattern of cannabis
use in the UK is unclear. Nevertheless, these data suggest that the
pattern of cannabis consumption is not straightforward among users;
and that there may at least be a tendency for young cannabis users to
seek high levels of intoxication (analogous to “binge drinking”), with
older users adjusting (titrating) their intake to achieve more moderate
and consistent levels of intoxication. However, we do not yet know if
the use of cannabis in the UK shows similar profiles of consumption;
nor whether there are changes in the pattern of use over time.
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4. Physical harms
4.1 As discussed in our previous reports [1, 2], cannabis can produce both
immediate and longer-term harm to physical health.
Effects on the circulation
4.2 Cannabis causes dilatation of some blood vessels but constriction
of others.
4.2.1 The characteristic redness of the eye, shortly after exposure, is due
to dilatation of the conjunctival blood vessels. Constriction of blood
vessels in other organs, however, causes a rise in blood pressure.
Paradoxically, cannabis can disrupt the control of blood pressure,
leading to a lower standing blood pressure and an increased risk of
fainting when standing up.
4.2.2 Cannabis produces an increase in heart rate which is maximal within
15 to 30 minutes of inhalation and remains elevated for about two
hours.
4.2.3 The effects of cannabis on the heart and blood vessels are similar to
the effects of moderate exercise and do not constitute a risk in healthy
adolescents or adults. Furthermore, tolerance occurs with repeated use.
Cannabis may, however, be dangerous for people with diseases of the
circulatory system, particularly those with coronary artery disease,
irregularities of heart rhythm or raised blood pressure or those at an
increased risk of stroke.
Effects on the respiratory system
4.3 Unlike sedative intoxicants such as diamorphine and barbiturates,
cannabis does not cause respiratory depression or suppress the gag
reflex even during extreme intoxication.
4.3.1 Cannabis has been reported to produce short-term modest dilatation of
the normal airways but – paradoxically – it can worsen asthma.
4.3.2 Smoking cannabis is associated with longer-term damage to the
respiratory tract and the lungs, with an increased risk of chronic
bronchitis. There is also a potential long-term risk of lung cancer. Severe
cases of lung damage (bullae formation) have been reported in young
heavy cannabis users. The extent to which these longer-term effects are
causally related to cannabis use is uncertain: such changes also occur
in people who use tobacco over long periods of time. In Britain,
cannabis is commonly smoked with tobacco. Due to the nature of
cannabis use, fewer joints are smoked by an individual over long periods
compared with cigarettes. The Council therefore considers that smoking
cannabis, even when mixed with tobacco, is less likely to harm lungs
than if tobacco is used alone.
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Effects on the reproductive system and reproduction
4.4 Cannabis use may have adverse effects on the reproductive system and
reproduction.
4.4.1 The effects of cannabis on fertility are uncertain. However, chronic use
of cannabis has been alleged to decrease sperm counts and sperm
motility in men and to suppress ovulation in women.
4.4.2 A small number of women use cannabis during pregnancy. Use is
associated with low birth weight babies and there have been
suggestions of an increase in minor birth defects. In addition, there is
some evidence that cannabis use during pregnancy may produce subtle
alterations in the neuropsychological performance of the child. All these
effects are seen in women who use tobacco during pregnancy and it is
not possible to be certain that cannabis itself causes additional harm.
Nevertheless, pregnant women should be warned to avoid both cannabis
and tobacco.
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5. Short-term harms to mental health
5.1 Cannabis can produce both immediate and longer-term harms to mental
health.
Acute psychological reactions
5.2 Cannabis use usually gives rise to pleasurable feelings of relaxation and
euphoria. In some people, however, acute intoxication leads to panic
attacks, paranoia and confused feelings that drive users to seek medical
help. These effects are generally short-lived and usually respond to
reassurance or the administration of a minor tranquilliser. In some
instances, acute cannabis intoxication appears to precipitate a
psychotic state that may continue for some time and require treatment
with antipsychotic drugs. This is similar to the psychotic states
following intoxication with cocaine or amphetamine but less severe than
for smokable forms of crack cocaine (“crack”) and methylamphetamine
(“ice”). A Danish study [12] has shown that about half of people with a
diagnosis of cannabis-induced psychosis experience further psychotic
episodes over the following three years, although whether this relates to
continuing cannabis use is not known.
5.2.1 The prevalence of these acute psychological reactions to cannabis is
uncertain. Nevertheless, unpublished data from the National Poisons
Information Service [13] show a decrease in the proportion of enquiries
relating to the acute toxic effects of cannabis between 2004 and 2007,
from around 0.4% to under 0.3%. Although these data are related to
enquiries – rather than confirmed diagnoses – they do not suggest that
there has been a recent increase in acute poisoning from cannabis with
the availability of higher-potency products. The Hospital Episode
Statistics data (for England) on cannabis poisoning for the same time
period show a similar downward trend [13].
Effects on psychomotor performance
5.3 As well as the pleasurable effects of relaxation and euphoria, the short-
term actions of cannabis may also include altered perceptions of space
and time, impaired learning and memory, difficulty in problem-solving
and loss of co-ordination [2].
5.3.1 Simulated driving studies indicate a dose-dependent impairment of
performance after cannabis use [14]. Moreover, such studies have
shown that this impairment of driving ability is more pronounced in the
presence of alcohol at blood levels around half the current legal limit
[14, 15].
5.3.2 Epidemiological studies in the UK and elsewhere have shown that
cannabis is the most common illicit drug found in the body fluids of
those having motor vehicle injuries [14]. The interpretation of these
findings is complicated by the frequent concomitant presence of alcohol
and by the long persistence of THC metabolites (three to four weeks) in
body fluids after cannabis use (and well after its psychomotor-impairing
effects would have dissipated).
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5.3.3 A recent case-control study [16], conducted in France, has investigated
the relative contributions of cannabis, alcohol, opiates and cocaine to
fatal road accidents. A positive test for cannabis was linked to an
increased risk of responsibility for the accident (taking account of
factors including alcohol). Moreover, a significant dose-related effect
was observed. At least 2.5% of fatal traffic accidents were thought to
be due to cannabis use, compared with 28.6% for alcohol3. This study
also confirmed the existence of an interaction between alcohol and
cannabis.
5.3.4 There continues to be clear evidence to support the Council’s previous
warnings [1, 2] against the use of cannabis by drivers, aircraft pilots
and those operating heavy machinery, as well as military, health and
emergency personnel.
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3 The adjusted odds ratio (taking account of factors including alcohol) for the presence of any THC in blood
was 2.37 (95% confidence interval 1.89 to 2.97) with a positive concentration response. By comparison,
the adjusted odds ratio for the presence of any alcohol was 9.50 (95% confidence interval 8.04 to 11.2).
In this case the odds ratio is the ratio of the probability of having an accident in a population with
cannabis or alcohol detected in the blood and the probability of having an accident in a population
without any drug being detected.
6. Dependency
6.1 Drug dependence is a process whereby repeated use leads to an
increasing difficulty in stopping. It is a complex phenomenon and its
nature differs from drug to drug, but is also dependent on the duration
and quantity that is used as well as characteristics of the user [1, 2].
Dependence is also related to the pleasure that a drug gives: the more
immediate pleasure a user experiences, the more likely it is to cause
dependence. It is reflected in an increasing reliance on the drug and by
symptoms of withdrawal when users reduce their consumption or
attempt to stop.
6.2 Dependence on cannabis alone is, unquestionably, a real phenomenon
[1, 2]. Studies among cannabis users have revealed that when they stop
they experience physical withdrawal as part of a dependence syndrome
characterised by decreased appetite, weight loss, lethargy, irritability,
mood changes, tremor, muscle pain, sweating and insomnia. There is
also a psychological craving for the substance. Reinstating the drug
terminates these symptoms. It has also been shown that cannabis
dependence is associated with an altered function of cannabinoid
receptors; and that withdrawal can be precipitated by a cannabinoid
receptor antagonist.
6.3 Data on the extent of cannabis dependence in the UK, from a study
carried out in 1999, is shown in Table 3 [17]. It should be noted that
the threshold for dependence used in this study was low; and that
individuals who were frequent users (i.e. daily users for a fortnight or
more), or who had developed tolerance for the drug so required more to
get the same effect, were assessed as dependent. These data therefore
almost certainly overestimate numbers requiring professional help in
stopping. They nevertheless provide some indication of the scale of
the problem.
Table 3
Prevalence of cannabis dependence alone [17]
Age group Prevalence (percentage of the population)
(years) Males Females
16–19 7.7 1.8
20–24 12.7 7.6
25–29 9.2 2.7
30–34 4.8 1.6
35–39 1.9 1.4
40–44 1.4 1.0
45–49 2.9 3.0
All (16–74) 3.7 1.4
6.4 The numbers of individuals reported [18] by the National Drug
Treatment Monitoring System (NDTMS) presenting for treatment in
relation to cannabis use for the years 2004/05 to 2007/08 [18]
(projected) are shown in Table 4. Changes to the data collection
procedures do not permit direct comparisons with earlier years. Data
for those under 18 years old is only included from 2005/06 as the
NDTMS was not operational in most young people’s treatment providers
until then.
CANNABIS: CLASSIFICATION AND PUBLIC HEALTH
13
Table 4
New presentations for treatment with cannabis as the main
problem [18]
Year Under 18 years old Over 18 years old
2004/05 – 6,890
2005/06 7,308 8,192
2006/07 7,603 8,041
2007/084 8,200 8,450
6.4.1 The young people’s treatment system provides services to those in
whom drug use is part of a pattern of behaviour including offending,
truancy and relationship difficulties with families. The level of cannabis
use that the intervention addresses is usually much less severe than in
older persons: it rarely involves dependency and the nature of the
intervention is very different [18]. The data in Table 4 therefore provide
little indication as to the true prevalence of cannabis-dependency in
young people.
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4 Projected (based on data to the end of 2007). Note: the increase may in part reflect the growth of
treatment service places over the time period. As a proportion of the total treatments given those for
cannabis dependence have probably fallen.
7. Effects in individuals with established schizophrenia
7.1 As discussed in our previous reports [1, 2], there is clear evidence that
the use of cannabis may worsen the symptoms of schizophrenia and
lead to relapse [19, 20]. The high prevalence of cannabis use, as well
as the use of other controlled substances among those with
schizophrenia or psychotic disorder [21, 22], is not well understood.
Nevertheless, there are clear and obvious harms associated with the
use of cannabis by people with psychotic disorders, and recent studies
[23, 24] confirm this. The Council’s clinical experts report, anecdotally,
that dealing with cannabis use (including dependence) is now a major
element in the clinical management of many young men with
established psychotic illnesses.
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8. Long-term psychotic illnesses (including schizophrenia)
Definitions and analysis
8.1 Psychotic symptoms are classically defined as disordered thinking,
delusions (abnormal beliefs) and hallucinations (abnormal perceptual
experiences). Many people – possibly up to 20% of the population –
experience psychotic symptoms at some period of their lives. To meet
the criteria for a “psychotic illness”, these symptoms generally need to
meet a threshold of severity, last for a significant period of time, and
have an adverse impact on the person’s social functioning [2].
8.1.1 The term “schizophreniform disorder” is used to describe a condition in
which psychotic symptoms that are characteristic of schizophrenia are
present but only for a relatively short period [2]. For some it is a
transient condition from which they make a complete recovery.
8.1.2 Schizophrenia [25] is a serious mental illness affecting about 0.5% of
the UK population over the course of their lives. In addition to psychotic
symptoms (which are usually prominent), patients with schizophrenia
have other problems including loss of motivation, disturbances of
behaviour and cognitive defects. These symptoms tend to be enduring
and disabling and, in a proportion of those affected, are life-long [2].
8.2 There has been growing concern over the past few years as to whether
cannabis use might precipitate chronic, or enduring, psychotic illnesses
including schizophrenia. In view of the ability of cannabis to precipitate
relapse in individuals with established schizophrenia, it is clearly a
biologically plausible hypothesis.
8.3 As discussed in our previous report [2], there are very considerable
difficulties in establishing a “cause and effect” relationship between the
use of cannabis and the subsequent development of a psychotic illness.
8.3.1 An association between cannabis use and the subsequent development
of a psychotic illness does not necessarily indicate a causal relationship
in either individuals or populations. The onset of schizophrenia usually
occurs in the late teens or early twenties; and it is at this age that
cannabis use is most prevalent. A temporal association – which may not
necessarily be a causal one – is therefore almost inevitable [2].
8.3.2 Because schizophrenia is relatively uncommon, most studies examining
the effects of cannabis on mental health have used the presence of
psychotic symptoms to examine its effects. As already discussed in
Section 8.1.1 above, conditions described as psychotic symptoms or
schizophreniform disorders do not necessarily lead to the long-term
disability that is so common in schizophrenia.
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8.4 Studies have, inevitably, been observational rather than experimental.
These observational studies have been necessarily controlled by
obtaining information about cannabis use from individuals without
psychotic symptoms and the results expressed as an “odds ratio”5 or
“relative risk”.
8.5 The interpretation of these studies, which have attempted to examine
the association between the use of cannabis and the development of
schizophrenia, is made very difficult for several reasons.
8.5.1 Studies, generally, have relied on the self-reported use of cannabis,
which may either overestimate or underestimate actual consumption. In
addition, studies have not necessarily sought information about the use
of other drugs of misuse such as amphetamines, which can also provoke
psychotic symptoms. Even where they have done so, there may be
significant discrepancies [26] between self-reported use and the results
of objective tests of consumption.
8.5.2 Studies have varied in the methods used to detect psychotic symptoms.
Only one study [26] has had the statistical power to assess whether
cannabis use precedes the onset of an illness that meets the full
diagnostic criteria for schizophrenia.
8.6 There are also factors that complicate the interpretation of any
observed association between schizophrenia and cannabis misuse.
There is some evidence that the use of cannabis, in some individuals,
may be the consequence of an emerging psychotic illness (sometimes
called reverse causality). The distinction between psychotic symptoms
occurring as a result of acute intoxication from cannabis rather than as
part of an enduring psychotic illness may not necessarily be clear.
Studies have therefore reported the adjusted estimates of the “crude”
odds ratios to take account of these, and other, factors that might
affect the association or relationship.
8.7 A recently published, high-quality, systematic review [27] has
synthesised the totality of the available published evidence. This review
has also attempted to take account of various sources of bias and
confounding factors in estimating the risks of a psychotic outcome
associated with the use of cannabis.
8.7.1 The adjusted odds ratios [27] in the pooled analyses of “ever” users of
cannabis were:
• 1.41 (95% CI6 1.20 to 1.65) for any psychotic outcomes; and
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5 The odds ratio is a measure of association between a condition and a possible risk factor. An odds ratio
around 1.0 suggests no association; an odds ratio of <1.0 suggests an association that is beneficial; and an
odds ratio of >1.0 suggests a harmful association. The size of an odds ratio is an important factor in judging
whether an association may indicate a causal relationship. For example, the odds ratio linking smoking and
lung cancer is about 20 (representing a 20-fold increase in the likelihood of smokers developing lung
cancer). An odds ratio of this size indicates that smoking plays a crucial, though not necessarily sole, role
in causing lung cancer. The odds ratio for developing schizophrenia in someone with a first-degree relative
(i.e. parent, sibling or offspring) with the condition – compared with someone who has not – is about 10 (in
the absence of cannabis use). In this instance, the size of the odds ratio strongly suggests a causal role for
genetic factors.
6 Confidence interval.
• 2.58 (95% CI 1.08 to 6.13) for psychotic disorders (including
schizophrenia, schizophreniform disorder and other psychoses
requiring treatment).
8.7.2 In a pooled analysis of the six studies that sought to identify a dose-
response relationship from information about the frequency of use, there
was an increased risk of a psychotic outcome in individuals who used
cannabis most frequently [27], with an adjusted odds ratio (compared
with non-users) of 2.09 (95% CI 1.54 to 2.84).
8.7.3 It is striking that, in these studies, adjustments to their odds ratios to
take account of reverse causality and intoxication effects reduced them
by anything from 15% to 80% [27]. This raises the possibility that there
may be other, unidentified, factors that would further reduce the
magnitude of the association between cannabis use and the
development of a psychotic illness.
8.8 Cannabis use has increased, very substantially, in the UK and other
countries over the past 35 years. If there is a causal link between
cannabis use in adolescence and the development of schizophrenia, this
might be reflected in temporal changes in the incidence and prevalence
of the disorder.
8.8.1 In an Australian study [28], the relationship between cannabis
consumption and the prevalence of schizophrenia was examined in
cohorts of people born between 1940 and 1979. Despite a steep rise in
the prevalence of cannabis use, and a corresponding decrease in the
age of initiation of use, there was no evidence of a significant increase
in the incidence of schizophrenia.
8.8.2 There is no UK national register of those for whom a diagnosis of
schizophrenia has been made. At the request of the Council, Frisher and
Crome [29] examined the prevalence and annual incidence of diagnosed
schizophrenia and psychoses among cohorts of over 900,000 patients
attending 183 general practices in the UK between 1996 and 2005.
They observed that both the prevalence and annual incidence of
schizophrenia and the prevalence of psychoses have decreased over the
period of observation.
8.9 The association between the development of schizophrenia and the use
of cannabis has been modelled [30] using national survey data on
cannabis consumption between 1970 and 2002 and the estimated
national incidence of schizophrenia that was derived from a survey
conducted in 1999. The authors concluded that the shift in cannabis
consumption to more prolonged use, initiated at an earlier age, is
relatively recent; and that its full impact may not yet be apparent.
If there is a causal relationship this should be seen within the next
five years.
8.10 The Council concluded that the evidence supports a causal association
between the use of cannabis, in adolescence, and the later development
of schizophrenia; although the evidence for this relationship is clearly
more complicated than when it considered this previously. The Council
also considered that the evidence supporting a dose-response
relationship was more persuasive than previously. The Council remains
uncertain about whether early cannabis use, before the age of 15 years,
ADVISORY COUNCIL ON THE MISUSE OF DRUGS
18
is associated with an additional increased risk. Nevertheless, the
magnitude of the effect of cannabis use on the subsequent development
of schizophrenia does not appear to be substantial, in the population as
a whole, with the cannabis preparations used during the late 1990s.
8.10.1 The peak incidence of schizophrenia in males (aged 20 to 24 years) is
approximately 15.9 per 100,000 person years, and in females (where
the peak incidence is at age 25 to 29 years) the peak incidence is 7.5
per 100,000 person years [31]. Assuming that heavy users of cannabis
have a two-fold increased risk of developing schizophrenia, based on the
model discussed earlier [30], it can be estimated that the increase in
annual risk:
• for males (aged 20 to 24 years) would be 1 in 3,100 to 1 in 1,900;
and
• for females (aged 25 to 29 years) would be 1 in 9,900 to 1 in 5,300.
Based on these figures, this means that to prevent one case of
schizophrenia in men aged 20 to 24, about 5,000 men would have to be
prevented from ever smoking cannabis [32].
8.11 It is evident that the majority of young cannabis users do not develop
psychotic illnesses. Those who do so must have one or more
predisposing factors. As discussed in our earlier report [2], the
existence of a functional polymorphism of the catechol-O-
methyltransferase gene (COMT) [33] has been described; which was
with an odds ratio for schizophreniform disorder of 10.9 (95% CI 2.2 to
54.1). This association, however, has not been confirmed in a more
recent study [34]. COMT status also has an impact on tobacco
dependence and so may be a factor in dependence on smoked cannabis.
COMT therefore could be a common mediating factor of both cannabis
use/dependence and psychotic outcomes.
Anxiety and depression
8.12 Associations between the use of cannabis and the subsequent
development of affective outcomes (depression, bipolar disorder and
anxiety) have been examined in a number of studies [2]. The
interpretation of these associations, however, is even more problematic
than those between cannabis use and schizophrenia and psychoses
[2, 27].
8.13 The systematic review [27] referred to previously undertook a synthesis
of the published studies examining the associations between cannabis
use and the development of affective disorders. Overall, the evidence for
associations between cannabis use and these affective disorders was
less strong than for psychotic outcomes, with confounding factors likely
to explain the reported associations.
8.13.1 A pooled analysis [27] of studies investigating an association between
frequent cannabis use and depression revealed an adjusted odds ratio of
1.49 (95% CI 1.15 to 1.94). The data on associations between cannabis
use and either bipolar disorder or anxiety were considered to be
inappropriate for meta-analysis.
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The gateway theory
8.14 The “gateway theory” is the term that describes the possibility that use
of cannabis leads to use of more dangerous drugs such as opiates and
cocaine [1]. It arises from the observation that users of the most
harmful (Class A) drugs have generally used cannabis first. The
interpretation of these studies is extraordinarily difficult because of the
confounding effects of alcohol, tobacco, solvents, stimulants and
psychedelic drugs, whose use frequently precedes that of Class A drugs.
Moreover, although there is no evidence that there are physiological
mechanisms leading to more harmful drugs, the social milieu of drug
use may result in some users trying them. The shared market for
cannabis and other drugs would increase the potential for escalation.
8.15 In 2002, the Council concluded that it was not possible to state, with
certainty, whether or not cannabis use predisposes users to dependency
on Class A drugs [1]. Nevertheless, it considered the risks to be small
and certainly less that those associated with the use of alcohol and
tobacco. No further convincing evidence has been identified by the
Council to alter this conclusion.
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9. Societal harms
Effects on performance
9.1 Smoking cannabis generally produces feelings of relaxation sometimes
accompanied with social withdrawal; but, unlike alcohol, it does not
appear to cause disinhibition, an increase in risk-taking behaviour or
aggression [2]. Psychometric laboratory studies confirm that, in
recreational users, cannabis has dose-dependent effects on motor
control, executive functioning and motor impulsivity but no action on
risk-taking [35].
9.2 Cannabis thus impairs the performance of tasks that require sustained
attention and motor control such as driving, operating heavy machinery
and flying aircraft (Section 5). In these circumstances, cannabis can be
dangerous to the individual and to others (especially when taken with
alcohol). Recent use of cannabis would also be expected to impair
learning at school or college, as well as having an adverse effect on
those whose employment requires cognitive skills. As well as the
personal costs to individuals, there are unquantified, but real, economic
costs to society.
Criminal and anti-social behaviour
9.3. A study among 11 to 19-year-old cannabis users showed that cannabis
transactions among young people were social rather than commercial
[8]; and that they were not overtly linked to criminal markets.
9.3.1 Buying with friends – “chipping in” – was the most common way of
purchasing cannabis because it allowed young people access even when
they had only small amounts of money. Most purchases were from
friends, friends of friends, or family members. Only 6% had bought
cannabis from an “unknown seller”.
9.3.2 The median expenditure on cannabis of these respondents was £20 per
week. Almost half of them funded this with money from parents or other
family members; and one third from their wages. Very few stated that
they funded their use through criminal activity such as theft or selling
cannabis.
9.4 In interviews with 61 young people, McSweeney [36] noted that the
majority funded their use of cannabis through pocket money and work
income.
9.5 A survey [37] of 100 young people aged between 16 and 24 years who
spent between £40 and £100+ per week on cannabis indicated that the
use of cannabis enabled them to relax, relieve boredom and enhance
otherwise mundane, everyday activities. Nevertheless, young people
also identified negative personal and social impacts, including lower
academic attainment, poorer relationships with their parents and the
possibility of getting a criminal record. Less than half the respondents
stated that they had engaged in any activity they would regard as
anti-social after smoking cannabis, and few suggested there was
a causal link.
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Cultivation of cannabis
9.6 Cannabis – as cannabis resin or the traditional herbal product – was,
until relatively recently, mainly imported from Morocco or the Middle
East. Over the past few years an increasing number of domestic
cannabis farms have appeared in England and Wales [38]. These farms
use hydroponic techniques and growth acceleration methods that allow
farmers to grow three to four crops per year. The profits from such farms
have been estimated to range from £90,000 to £480,000 per year [38].
The product of these farms is almost entirely sinsemilla; and UK-sourced
material now appears to supply the majority of cannabis users in the UK.
9.6.1 A significant factor in the domestic production of cannabis in the UK
has been the emergence of cannabis farms and the activities of criminal
groups, some using illegal Vietnamese immigrants (some as young as
13) as “gardeners” to attend to the crops [38]. The criminal gangs,
some with connections to Vietnam and China, provide the initial
financial outlay and give advice on the setting up of farms (including the
bypassing of electricity meters to provide power), as well as the method
and timing of the collection of harvests.
9.6.2 A survey conducted by the Association of Chief Police Officers (ACPO)
in late 2007 asked forces across England and Wales to provide data on
the numbers of cannabis farms seized during the year [38]. The 19
responders had, between them, discovered 1,564 farms over the
previous 12 months. The cannabis farms were not confined to rural
areas. The Metropolitan Police, over the past two years, has been
discovering farms in domestic properties at the rate of about 10 per
week in London.
9.6.3 ACPO and the Association of Chief Police Officers in Scotland (ACPOS)
are also concerned that the proceeds of cannabis farms will be used to
diversify into other areas of crime, with the attendant risks to safety and
public confidence.
9.6.4 ACPOS has documented a significant increase in the number of
industrial-scale cannabis farms discovered in Scotland from single
figures in 2005/06 to more than 70 in 2006/07.
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10. Potency
10.1 As discussed earlier (see Section 2.2), the main psychoactive
constituent of cannabis is THC, although other constituents may play a
role. In particular CBD has been shown to antagonise the effects of THC
in animal models, so changes in the relative amounts of this and THC
might alter the effects of cannabis, though there is little evidence for
this in humans at present [3, 4].
10.2 The Council noted, in its previous report [2], that scientific studies of
the potency of cannabis products pose technical and practical problems.
10.2.1 The estimation of cannabis potency is based on material seized by the
law enforcement agencies. This may not be representative of the
cannabis used by consumers.
10.2.2 The analysis of the THC content of cannabis products is difficult [2].
THC is not distributed homogeneously in cannabis plants; extraction of
THC from plant material for chemical analysis may be uncertain; and the
precision of the measurement techniques varies with the method used.
10.3 There has, for many years, been a wide (ten-fold) variation in the THC
content of samples of both traditional imported cannabis and sinsemilla.
Sampling error, when only small numbers of seizures have been
submitted for analysis, may therefore be considerable.
10.4 Data on the THC content [39] of material examined by the Forensic
Science Service, since 1995 are shown in Table 5. There has been no
consistent change in the THC content of resin and traditional herbal
cannabis over this time period. There was a clear increase in the THC
content of sinsemilla between 1995 and 2000 but this appears to have
remained broadly constant from 2000 to 2007.
10.4.1 A separate study [40], based on material (n = 452) provided by five
English police forces and obtained during 2005, showed that the median
THC content of cannabis resin and traditional herbal cannabis was 3.5%
and 2.1% respectively (Table 6). This is consistent with the data in
Table 5. The median THC content of sinsemilla was 13.9%, which is
again consistent with the data in Table 5. As with previous studies,
a wide range in THC content was noted for all three cannabis
preparations. Comparable results have been reported from a smaller
UK study [41] and similar increases in the THC content of cannabis
products have been observed elsewhere in Europe [42, 43].
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Table 5
Mean THC content (%) of cannabis products, 1995–2007 [39]
Traditional
imported
Year Sinsemilla Resin herbal cannabis
1995 5.8 No data 3.9
1996 8.0 No data 5.0
1997 9.4 No data 4.0
1998 10.5 6.1 3.9
1999 10.6 4.4 5.0
2000 12.2 4.2 8.5
2001 12.3 6.7 No data
2002 12.3 3.2 No data
2003 12.0 4.6 No data
2004 12.7 1.6 No data
2005 13.7 5.5 1.9
2006 10.8 2.7 2.1
2007 10.4 4.5 2.6
10.4.2 The study by Potter (2005), however, also reported [40] the results of
analyses of other cannabinoids, including CBD (Table 6). This showed
that, unlike resin, traditional herbal cannabis and sinsemilla appear to
have little or no CBD (at least in these samples) but with wide ranges
between samples.
Table 6
Median THC and CBD content (%) in material seized in 2005 [40]
Traditional
Sinsemilla Resin imported herbal
Cannabinoid (range) (range) cannabis (range)
THC 13.98 3.54 2.14
(1.15–23.17) (0.44–10.76) (0.28–11.81)
CBD <0.10 4.17 <0.10
(<0.10–0.56) (0.36–6.97) (<0.10–1.97)
10.5 A very recent (unpublished) study [44] has reported the results from
samples (n = 1,756) confiscated by police officers in England and
Wales7 when issuing warnings for possession. None of these samples
were obtained for the purposes of criminal proceedings under the
Misuse of Drugs Act.
10.5.1 The THC and CBD content of these samples are shown in Table 7 and
are comparable with the findings shown in Table 6.
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7 The Council does not have comparable data available for the other devolved administrations but there is
no reason to believe that the situation in Tables 5 and 6 is substantially different.
Table 7
Apparent market share (%) and mean THC and CBD content (%) of
cannabis products8 [44]
Market share/ Sinsemilla Resin Traditional
cannabinoid imported
herbal
cannabis
Market share 80.8 14.6 2.1
THC content 16.1 5.9 8.3
(range) (4.1–46.0) (1.3–27.8) (0.3–22.0)
CBD content ∼0.1 3.5 ∼0.1
10.6 The available evidence therefore confirms that sinsemilla now appears
to dominate the cannabis market and to have a substantially higher THC
content than cannabis resin or traditional herbal cannabis and minimal
quantities of CBD. Whether THC content of cannabis resin, traditional
herbal cannabis or sinsemilla has changed since our previous report [2]
is less clear because the results of the analyses in Tables 6 and 7
represent results from heterogeneous samples.
10.7 It remains unclear as to how much THC is smoked in a typical joint.
Some of the material shown in Table 6 was obtained from joints
(and mixed with tobacco) but some was in the natural form.
Moreover, there is some evidence – though not from the UK – that some
cannabis smokers seek the maximum effects while others inhale only a
sufficient quantity of THC to obtain a particular degree of intoxication
(Section 3.4).
10.7.1 A parallel can be drawn between the use of high-strength cannabis and
the consumption of alcohol. The public health consequences of alcohol
use are not a simple function of the strength of the beverage. Rather, at
a population level, it is the total quantity of alcohol that is consumed.
10.7.2 If the parallel with alcohol is taken further, the propensity for some
young people to “binge drink” alcohol becomes analogous to the Dutch
findings that some young people “binge smoke” cannabis.
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8 Some 2.6% of samples did not appear to comprise cannabis.
11. Public attitudes to cannabis
11.1 The Council’s responsibility in advising on the control of drugs is
concerned solely with assessing their harmfulness to individuals and to
society. Nevertheless, the Council is aware of the public’s anxieties
about the nature and extent of substance misuse generally and of
cannabis in particular.
11.2 In July 2007, the government launched a wide-ranging consultation on
its proposals for a new drug strategy. This included two questions
specifically related to cannabis:
Q39a – The Prime Minister announced on 18 July that he will ask the
Advisory Council on the Misuse of Drugs to look at whether cannabis
should be reclassified from a Class C drug to the more serious Class B.
This is because of concerns about stronger strains of the drug,
particularly skunk, and the potential mental health effects they can
have. Do you think cannabis should be reclassified and, if so, why?
Q39b – Are there any other changes that you would wish to see 
and, if so, why?
11.2.1 Of the 639 individuals and organisations responding to these questions,
44% wished cannabis to remain Class C; 19% wished it to become a
Class B substance; and 19% wished it to be legalised. One hundred and
sixteen respondents were undecided.
11.2.2 The Council considered that, although these findings represent the
responses of groups and individuals with a particular interest in, or
concern for, the classification of cannabis, they did not necessarily
reflect the views of the wider public.
11.3 The Council is aware of numerous claims that the public, generally, is
confused about the legal status of cannabis as well as its degree of
control under the Misuse of Drugs Act. The Council therefore
commissioned an opinion poll [45] to investigate the views of the wider
public on the classification of cannabis. The polling was carried out
between 11 and 13 January 2008 and involved 1,003 respondents [45].
11.3.1 Of those polled, 80% were aware that cannabis was an illegal drug, 4%
thought it was legal and 16% “did not know”. Of those who knew that
cannabis was illegal, 12% thought it was in Class A, 31% in Class B and
52% in Class C.
11.3.2 Responses to questions about the harmfulness of cannabis to individuals
and society are shown in Table 8.
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Table 8
Responses (%) to questions on harmfulness of cannabis to individuals
and society [45]
Strongly Tend to Tend to Strongly Don’t
Question agree agree Neutral disagree disagree know
Cannabis does not give rise 10 15 13 20 29 12
to physical health problems
(e.g. cancer)
Cannabis has associated 50 30 9 3 3 6
mental health risks for users
Strains of cannabis have 39 22 13 2 1 23
become stronger within the
past 10 years
Cannabis use contributes to 43 24 9 13 6 5
social disorder (e.g. anti-social
behaviour)
Cannabis use contributes to 42 24 12 12 6 3
an increase in criminal activity
11.3.3 When asked about in what class cannabis ought to be, 32% considered
that it should be in Class A, 26% Class B and 18% Class C, while 13%
stated that they “did not know”. However, when they were asked to
consider what penalties ought to be applied for possession, 11%
considered seven years’ imprisonment (equivalent to Class A), 13%
five years (equivalent to Class B) and 41% two years (equivalent to
Class C), and 27% considered that there should be no penalty [45].
11.3.4 Assuming that the results of this poll can be generalised to the
population as a whole (and there is no evidence to the contrary), it is
clear that the majority of the public are aware that cannabis is an illegal
substance even if they are unclear about its precise classification under
the Misuse of Drugs Act. The public also accepts that cannabis is a
hazard to mental health. The results of the survey indicate that the
public considers cannabis to be responsible for social harms (anti-social
and criminal behaviour).
11.3.5 Although a majority of respondents wished for cannabis to be
reclassified as a Class A or B substance, there seems little desire for
the penalties for possession to increase. The sole legal consequence
of reclassifying cannabis to Class B would, of course, be to increase
the penalty for possession from two to five years and there is,
therefore, some inconsistency in the responses with respect to
the classification system.
11.4 A number of non-governmental organisations with interest in, and
concern for, the classification of cannabis made written and/or oral
representations to the Council. Some, particularly those representing
sufferers of the perceived mental health effects of cannabis, were
strongly in favour of reclassification largely because of the signal this
would send to the public about the dangers of this substance. Others
wrote, or spoke, with equal passion claiming that the reclassification
of cannabis would serve no useful purpose and that it would lead to
greater criminalisation of young people; and challenging the claim
that it would send a useful public health message. A number of
written representations in favour of legalisation were also received
by the Council.
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11.5 The Council also learned of international experience on changes to the
classification of cannabis [46] where removal of criminal sanctions for
personal use, as for example in several Australian states, had been seen
as a success in reducing criminalisation of users and improving the
likelihood that those with dependency would seek treatment.
ADVISORY COUNCIL ON THE MISUSE OF DRUGS
28
12. Discussion
Epidemiology of cannabis use
12.1 There is consistent evidence, from different sources (Section 3), that the
use of cannabis appears to have diminished by around 20% to 25% over the
past five years. Nevertheless, use is still widespread, particularly among
young people. Cannabis use is of particular concern to the Council because
of the risks of precipitating relapse in those with schizophrenia (Section 7)
and of enduring psychotic illnesses (Section 8). Vigorous steps should
therefore be taken to minimise the supply of cannabis in the vicinity of
psychiatric institutions and prisons, as well as educational establishments
and extra-curricular and non-school facilities provided for young people,
such as youth clubs.
12.2 Emerging evidence suggests that some cannabis users may titrate their
doses of THC to achieve a particular intensity of effect (Section 3.4).
Other users, however, may attempt to obtain the maximum intensity of
effect. This evidence of “binge smoking”, albeit in the Netherlands
(Section 3.4), is of special concern in the light of the data indicating the
greater use of cannabis products with higher THC content (Section 10)
and the risks to long-term mental health (Section 8).
Physical harms
12.3 Although cannabis causes physical harm to individuals (Section 4), the
Council is unaware of significant new evidence since its last report. It
continues to consider that the physical harms of cannabis are no greater
than those associated with the use of other Class C substances such as
benzodiazepines or gamma-hydroxybutyrate GHB. Nevertheless, there are
people at particular risk, including asthmatics, those with heart or
circulatory complaints, men and women seeking to have children and
pregnant women. Special efforts should be made to discourage use in
these groups of people.
Short-term harms to mental health
12.4 The short-term effects of cannabis include acute intoxication reactions
and adverse effects on psychological and psychomotor performance
(Section 5).
12.4.1 The symptoms and signs of acute intoxication with THC are well
established and can generally be managed by reassurance and the use of a
minor tranquilliser. These symptoms and signs are substantially less than
those associated with Class B drugs such as amphetamine or barbiturates.
Although the available data (Section 5.2.1) are imperfect, there is no
evidence that there has been any increase in the incidence of acute
intoxication in the UK since the Council’s last report [2].
12.4.2 The effects of cannabis on psychomotor performance (Section 5.3),
including the results of studies in fatal road accidents (Section 5.3.3),
confirm the Council’s previous warnings against the use of cannabis by
drivers, aircraft pilots and those operating heavy machinery as well as
military, health and emergency personnel. In the Council’s judgement,
however, these adverse effects – and associated warnings – are not
dissimilar to other Class C drugs such as benzodiazepines.
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Dependence
12.5 There is clear evidence that cannabis can produce dependency as do
Class C drugs such as benzodiazepines (Section 6). The potential for
dependency does not, however, appear to be as great or florid as with
drugs such as diamorphine and cocaine or, indeed, amphetamines or
barbiturates [1, 2].
12.6 Despite the considerable limitations in the data on the need for service
provision in the treatment of cannabis dependency (Section 6.3), the
available information suggests that few dependent users are – for
whatever reason – accessing services. More needs to be done to identify,
and treat, those who are dependent on cannabis.
Effects in individuals with established schizophrenia
12.7 As discussed in the Council’s previous reports [1, 2], there is
unequivocal evidence that the use of cannabis by people with
schizophrenia increases the likelihood of relapse, manifested by a
worsening of symptoms and often accompanied by a refusal to continue
treatment (Section 7). The Council was concerned by anecdotal reports
of the apparent ease with which inpatients in psychiatric hospitals can
obtain cannabis from dealers. Efforts to discourage the use of cannabis
by those with schizophrenia should be coupled with attempts to ensure
that dealers are denied access to the vicinity of psychiatric institutions.
Long-term psychotic illness (including schizophrenia)
12.8 The evidence to support an association between the use of cannabis by
young people and the development of a psychotic illness (including
schizophrenia) is not entirely consistent (Section 8). There is a
significant increase in the risk of the development of a psychotic
illness (including schizophrenia) in controlled observational studies
(Section 8.7), but this does not appear to have been accompanied by
an increase in the incidence of psychotic illness or schizophrenia at a
population level (Sections 8.9 and 8.10). This may reflect a weak and
complex causal link, or some other factor(s) such as a common
predisposition to schizophrenia and also to cannabis use. Miller and
colleagues [47] reported that individuals at high risk, because of a family
history of schizophrenia, appeared to be susceptible to cannabis-related
illnesses if they had a history of certain behavioural problems between
the ages of 13 and 16 years.
12.9 On balance, the Council considers that the evidence points to a probable,
but weak, causal link between psychotic illness and cannabis use.
Whether such a causal link will become stronger with the wider use of
higher potency cannabis products remains uncertain.
12.9.1 Only a minority of young people who use cannabis will develop a
psychotic illness. Hickman and colleagues [33] estimate that around
5,000 young men, or 20,000 young women, would need to be prevented
from using cannabis to avoid one person developing schizophrenia.
(Section 8.10.1)
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Anxiety and depression
12.10 The Council remains unconvinced that there is a causal relationship
between the use of cannabis and the development of any affective
disorder (Sections 8.12 and 8.13).
Gateway theory
12.11 The Council does not consider the risks of progression to Class A drugs
as a consequence of using cannabis to be substantial; and considers
that such risks are likely to be less than those associated with the use
of alcohol and tobacco (Section 8.14).
Social harms
12.12 The adverse effects of cannabis on psychological and psychomotor
performance (Section 9.1, 9.2) are well-known and were noted in the
Council’s previous reports [1, 2]. The recent study, in France, of the
association between fatal road accidents and the presence of THC
emphasises the importance of the Council’s previous warnings about
the potential dangers of cannabis use among those driving, piloting
aircraft and operating heavy machinery as well as among professionals
in the health, military and emergency services [1, 2].
12.13 The evidence available to the Council does not suggest that cannabis
use is a substantial cause of acquisitive crime (Section 9.3).
12.14 Anti-social behaviour is an unlikely consequence of the known
psychological effects of cannabis itself (Section 9.5). There is, however,
a clear perception among the public that cannabis is associated with
anti-social behaviour. In the opinion of experts on the Council,
anti-social behaviour is probably largely exacerbated by alcohol. It is
therefore possible that the public regard smoking cannabis in the
presence of others as, in itself, a form of anti-social behaviour.
12.15 The Council recognises (and shares) the concern of the police at the
appearance, over the past three years, of very substantial numbers of
cannabis farms (Section 9.6). The involvement of “organised crime”, the
diversion of the farms’ profits into other (sometimes even more serious)
illegal activities, and the associated “people trafficking” (including
children) are unacceptable.
Potency
12.16 The Council considers that, since its last review [2], there is evidence
to suggest users of cannabis are now exposed to products with a higher
THC content than previously (Section 10). This has occurred largely
because of the substantial increase in the market share of sinsemilla.
The Council is therefore concerned at the dominance of sinsemilla in the
market because of its greater potency and the virtual absence of CBD.
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12.16.1 The consequences, however, are less easy to predict because, if users
titrate their intake to achieve a desired intensity of effect, the
“effective” THC dose for individuals may be unchanged. On the other
hand, if some users (especially younger males) “binge smoke” the
consequences may be very serious to their mental health.
12.16.2 It is worthy of note that despite the increase in cannabis potency there
has been no concomitant recorded increase in enquiries to the National
Poisons Information Service, nor an increase in hospital admissions due
to cannabis intoxication. 
Public perceptions and opinions
12.17 The views expressed in response to the specific questions relating to
cannabis in the consultation on the government’s drug strategy
depended on the nature and interests of respondents (Section 11). The
Council places greater weight on the polling data which show, in
contradiction to the assertion of many witnesses, that only 4% of the
public believe cannabis to be a legal substance. Although the public’s
knowledge of the details of the classification system is limited, there is
little desire for the penalties for possession to be increased from a
maximum prison sentence of two years to five years (Section 11.3.3).
12.18 Of the many individuals and non-governmental organisations who wrote
to the Council during this inquiry, roughly equal numbers were in favour
of the reclassification of cannabis to Class B as were in favour of
maintaining its Class C status.
12.18.1 Those seeking reclassification did so largely because they believed it
would send out a signal to young people about the dangers associated
with its use. Few, if any, however, wished to see the penalties for
possession to be increased. Only 24% of the sample polled wished
the penalties for possession to be increased while 67% sought for
the penalties for possession to be either unchanged or abolished
(Section 11.3.3).
12.18.2 Those who recommended that cannabis remain as a Class C substance
mainly considered that reclassification would serve no useful purpose,
cause confusion, and be less likely to result in criminal charges for
possession.
12.19 In its evidence to the Council, ACPO indicated that its desire for
cannabis to be reclassified to Class B was based on three factors:
• the 2004 change in classification has inadvertently provided an
opportunity for a greater, and flourishing, illegal market;
• the potential for cannabis users to suffer associated mental health
problems has increased; and
• policing cannabis as a Class C substance, while seen as a low policing
priority, is affecting public confidence.
12.20 ACPOS indicated in written evidence to the Council that the 2004
reclassification did not alter its approach to enforcement of the
legislation. ACPOS did not necessarily seek change for change’s sake,
but was clear in outlining its concerns regarding the harms associated
with cannabis.
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13. Conclusions and Recommendations
13.1 The Council is still very concerned about the widespread use of
cannabis among young people. Although the number of users have
decreased over the past few years, cannabis still poses a real threat to
the health of those who use it.
13.2 The Council hopes that the government, parliament and the public
appreciate that the use of cannabis is, ultimately, a public health
problem; and that it requires a public health response if current use and
the associated harms are to be substantially reduced. Although the
criminal justice and classification systems have a role to play –
especially in reducing supply – the major emphasis must be directed at
ways that drastically reduce demand (i.e. primary prevention), especially
in the young; and to provide help for those who are dependent on
cannabis (i.e. secondary prevention).
Recommendation 1: In the face of the widespread use of cannabis, a
concerted public health response is needed to drastically reduce its
use.
Recommendation 2: Special emphasis should be placed on developing
effective primary prevention programmes, directed at young people.
Classification
13.3 In advising the government on the classification of a substance the
Council is required, under the terms of the Misuse of Drugs Act, to
consider only its harmfulness to individuals and society. There is no
legal basis for the Council, in advising on classification, to take into
account matters such as the message that is conveyed to the public, or
the consequences for policing priorities.
13.4 Since the Council’s last review [2] further evidence has become
available about the harmfulness of cannabis to both individuals and
society.
13.4.1 The most worrying individual harms are the effects on mental health
but, since the Council’s previous review the evidence has become more,
rather than less, confused. Although there is a consistent (though weak)
association, from longitudinal studies, between cannabis use and the
development of psychotic illness, this is not reflected in the available
evidence on the incidence of psychotic conditions. The most likely (but
not the only) explanation is that cannabis – in the population as a whole
– plays only a modest role in the development of these conditions. The
possibility that the greater use of cannabis preparations with a higher
THC content might increase the harmfulness of cannabis to mental
health cannot be denied; but the behaviour of cannabis users, in the
face of stronger products – as well as the magnitude of a causal
association with psychotic illnesses – is uncertain.
CANNABIS: CLASSIFICATION AND PUBLIC HEALTH
33
13.4.2 Evidence about the social harms associated with cannabis is clearer.
Despite public anxieties, there is little real evidence that cannabis is a
significant cause of acquisitive crime or of anti-social behaviour. There
is, though, cause for concern about the growth of cannabis farms and
the emergence of wider organised crime, including people trafficking,
that is associated with them.
13.5 Decisions about advising on classification must, ultimately, be based on
the Council’s collective judgment about the relative harmfulness of
substances within, and between, classes. On balance, taking into
account the totality of the relevant issues and very mindful of the actual
and potential harms, the majority of the Council advises that cannabis
and the cannabinols remain in Class C. Although the majority of
members recognise the harms caused by the use of cannabis to
individuals and society, they do not consider these to be as serious as
those of drugs in Class B.
13.5.1 A minority of members of the Council remain very concerned about
effects of cannabis on the mental health of users, especially in the light
of the (now) wide availability and use of sinsemilla. In their view the
balance of harms more closely equates to substances in Class B than
Class C.
Recommendation 3: Cannabis should remain a Class C drug.
13.5.2 The Council anticipates that additional data will become available within
the next few years specifically relating to the causal association
between cannabis use and psychoses. The Council therefore proposes to
undertake a further review of the evidence in 2010.
Recommendation 4: The Council should convene a further review of
cannabis in two years’ time.
13.6 Irrespective of the classification of cannabis, the Council unanimously
advises that the government develop a full public health strategy under
the auspices of the Chief Medical Officers. The potential threat to public
health requires nothing less.
Recommendation 5: A public health strategy, designed to minimise the
harms from the use of cannabis, should be developed under the
auspices of the Chief Medical Officers.
13.7 A public health strategy should address each of the following issues.
Primary prevention
13.7.1 The government should be congratulated on its FRANK campaign.
Nevertheless, the Council recommends that a more generously
resourced campaign to alert young people to the dangers of cannabis
should be developed.
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Recommendation 6: A well-resourced campaign alerting young people to
the dangers of cannabis should be developed.
13.7.2 In addition, schools (including the independent sector) and local
authority youth services should be required to develop and publish their
policies relating to substance misuse. This should include the nature
and extent of the teaching given to children (as advised by the
Department for Children, Schools and Families), as well as the actions
taken when pupils are found possessing or dealing illegal substances.
The higher education sector should also (in view of the extensive use of
cannabis by undergraduate students) be requested to develop and
publish policies in relation to the actions taken where students or staff
are found in possession of illegal drugs, including cannabis, both for
personal use and for supply.
Recommendation 7: Schools and higher education establishments
should develop and publish policies on substance misuse.
13.7.3 Efforts to reduce the use of cannabis (as well as other controlled
substances) must also involve parents and families. Advice on what to
tell children about substance misuse, as well as advice regarding what
action(s) parents or other family members should take if they discover a
child is in possession of an illegal drug, should be made widely
available.
Recommendation 8: Credible and consistent advice and support should
be available for parents and families about the appropriate action(s)
they should take if their child is in possession of an illegal drug.
Secondary prevention
13.7.4 The extent of dependency on cannabis is unknown but significant.
Health professionals should be trained, encouraged and offered
resources to treat and support cannabis-dependent people in the
community and inpatient settings. Services to help people dependent on
cannabis should be widely available. There is some evidence that
tobacco smoking cessation services are less effective with patients
who are also dependent on cannabis. Efforts therefore need to be made
to explore the feasibility of combining treatment programmes for those
who are dependent on cannabis along with tobacco, alcohol and other
substances.
Recommendation 9: Health professionals should be encouraged to
identify, and offer help to, people dependent on cannabis. The health
departments should consider making recommendations for combining
cannabis treatment programmes with those of tobacco, alcohol and
other substances.
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Reducing supply
13.8 The criminal justice system has an important role to play in reducing
supplies of cannabis.
13.8.1 The Council fully supports the police in their wish to be able to devote
greater resources to restricting the importation and, most importantly,
the domestic cultivation of cannabis.
Recommendation 10: The Council strongly supports the police in being
able to devote greater resources to reducing cannabis supply,
particularly through restricting the domestic cultivation of cannabis.
13.8.2 The Council is concerned about the easy availability of paraphernalia
associated with cannabis use and its cultivation. The Council
recommends that the Home Office explores the potential for regulating
these activities, including whether it might be practical to bring
cannabis seeds within the scope of the Misuse of Drugs Act; and
whether appropriate warnings (including both tobacco and cannabis)
should be placed on packs of cigarette rolling papers.
Recommendation 11: The Home Office should assess the extent to
which the trade in cannabis paraphernalia might be more effectively
regulated.
13.8.3 As indicated at various points in the report, the Council has expressed
its concern that vulnerable people have easy access to cannabis. These
include children, university undergraduates, patients in psychiatric
hospitals or attending community psychiatric health services, and
prisoners. The Council therefore recommends that the Home Secretary
gives consideration to amending Section 4A of the Misuse of Drugs Act
1971 to incorporate additional aggravating factors including supply of a
controlled drug in the vicinity of any further and higher educational
establishments, psychiatric health institutions and prisons.
Recommendation 12: Additional aggravating factors should be
introduced into legislation concerning the seriousness of offences
involving the supply of controlled drugs.
Other measures
13.9 Warnings about the risks of cannabis to those with cardiovascular
disease and asthma as well as to women who are, or seek to become,
pregnant should be made widely available. Warnings about the risks of
cannabis in driving, flying aircraft or operating heavy machinery should
be emphasised. Those whose work requires cognitive skills should also
be made aware that cannabis may impair their performance.
Recommendation 13: Warnings regarding cannabis use among particular
at-risk groups should be emphasised.
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14. Research Recommendations
14.1 The scale and public health significance of current preparations of
cannabis use in the UK require further research if the harmful
consequences for future generations of young people are to be
substantially diminished. This should include considerations of effects
on families. Qualitative research on the impact of cannabis farms on
local people should be undertaken.
Recommendation 14: The scale and public health significance of
cannabis use in the UK require further research.
14.2 Efforts should be made to improve cannabis use data collected from
children and the general population. We understand that the Home
Office is considering the feasibility of including under-16s within the
British Crime Survey (or a separate similar survey). We would welcome
this approach and encourage the collection of drug-related data.
Recommendation 15: The Home Office should extend the British Crime
Survey to the under-16s and the survey should include drug use.
14.3 There is a real and urgent need for research into the sociology of the
use of cannabis. This should attempt, in particular, to assess how users
react to the more potent forms of cannabis; the extent to which people
engage in “binge smoking”; and to investigate the pharmacodynamics
and pharmacokinetics of those users who “titrate” their intake of THC.
Recommendation 16: Further research is required into the pattern of the
use of cannabis, dependency and the resulting physical and
physiological complications, particularly to assess how users react to
more potent forms.
14.4 There is also a need to continue to monitor the market share of
cannabis products as well as continuing to monitor their potencies in
relation to their THC and CBD content. Products purchased from
suppliers should also be considered. The possible protective role of CBD
needs to be fully evaluated in humans.
Recommendation 17: Continued monitoring of the market share of
cannabis and its potency should be undertaken.
14.5 Research into the prevalence of cannabis use and the trajectory of drug
use histories, especially the transfer from occasional use to dependency,
will enable mental health services to plan effective service provision.
Research is also required into the clinical and cost effectiveness of
measures designed to help people stop using cannabis. In addition we
need better data on the routes by which users access services.
Recommendation 18: Research is required into the clinical and cost
effectiveness of measures designed to help cannabis-dependent users
recover from their addiction.
14.6 Research is needed to identify those young people who may be at
particular risk (i.e. subgroups or those with “susceptibility factors”) of
developing enduring psychoses from the use of cannabis. Such
knowledge could usefully inform an effective public health campaign.
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Recommendation 19: Further research should be aimed at identifying
young people who may be at risk of developing enduring psychoses from
the use of cannabis.
14.7 Research aimed at clarifying possible associations between cannabis
use and psychosis should be extended. For instance, the Council
recommends a full evaluation of the General Practice Research
Database as a source of data for such enquiries. Given the possibility
that new high potency forms of cannabis have only recently been in
general use, it may be important to perform regular – possibly annual –
schizophrenia data collections from this source.
14.8 Data on the incidence and prevalence of schizophrenia should be
obtained in order to provide better estimates of the risks young people
run when they smoke cannabis. Such knowledge, again, would usefully
inform an effective public health campaign.
Recommendation 20: Data on the incidence and prevalence of
schizophrenia should be obtained in order to better estimate the risks to
young people when they smoke cannabis.
14.9 Although, currently, there are no available THC substitutes to prescribe
for withdrawal programmes, the newer CB1 and CB2 agonists and
antagonists that are now emerging might provide pharmacological
assistance for those seeking to stop cannabis use. In addition, by
analogy with buprenorphine for heroin dependence, cannabis agonists or
partial agonists might offer treatment options for cannabis dependence.
Recommendation 21: Further research on the biological mechanisms
involved in cannabis addiction, and the consequent potential
treatments, is needed.
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15. Recommendations
Recommendation 1: In the face of the widespread use of cannabis, a concerted
public health response is needed to drastically reduce its use.
Recommendation 2: Special emphasis should be placed on developing effective
primary prevention programmes, directed at young people.
Recommendation 3: Cannabis should remain a Class C drug.
Recommendation 4: The Council should convene a further review of cannabis in
two years’ time.
Recommendation 5: A public health strategy, designed to minimise the harms
from the use of cannabis, should be developed under the auspices of the Chief
Medical Officers.
Recommendation 6: A well resourced campaign alerting young people to the
dangers of cannabis should be developed.
Recommendation 7: Schools and higher education establishments should develop
and publish policies on substance misuse.
Recommendation 8: Credible and consistent advice and support should be
available for parents and families about the appropriate action(s) they should
take if their child is in possession of an illegal drug.
Recommendation 9: Health professionals should be encouraged to identify, and
offer help to, people dependent on cannabis. The health departments should
consider making recommendations for combining cannabis treatment
programmes with those of tobacco, alcohol and other substances.
Recommendation 10: The Council strongly supports the police in being able to
devote greater resources to reducing cannabis supply, particularly through
restricting the domestic cultivation of cannabis.
Recommendation 11: The Home Office should assess the extent to which the
trade in cannabis paraphernalia might be more effectively regulated.
Recommendation 12: Additional aggravating factors should be introduced into
legislation concerning the seriousness of offences involving the supply of
controlled drugs.
Recommendation 13: Warnings regarding cannabis among particular at-risk
groups should be emphasised.
Recommendation 14: The scale and public health significance of cannabis use in
the UK require further research.
Recommendation 15: The Home Office should extend the British Crime Survey to
the under-16s and the survey should include drug use.
Recommendation 16: Further research is required into the pattern of the use of
cannabis, dependency and the resulting physical and physiological complications,
particularly to assess how users react to more potent forms.
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Recommendation 17: Continued monitoring of the market share of cannabis and
its potency should be undertaken.
Recommendation 18: Research is required into the clinical and cost
effectiveness of measures designed to help cannabis-dependent users recover
from their addiction.
Recommendation 19: Further research should be aimed at identifying young
people who may be at risk of developing enduring psychoses from the use of
cannabis.
Recommendation 20: Data on the incidence and prevalence of schizophrenia
should be obtained in order to better estimate the risks to young people when
they smoke cannabis.
Recommendation 21: Further research on the biological mechanisms involved in
cannabis addiction, and the consequent potential treatments, is needed.
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Annex F: Glossary of Terms
Bong: A water pipe that consists of a vertical tube partially filled with liquid, and a
smaller tube ending in a mouthpiece. It is used to smoke a variety of substances
including cannabis.
Cannabis resin: Material produced by mechanically separating the resinous parts of
Cannabis sativa from the rest of the plant and typically presented as fine-grain
compressed blocks.
Confidence Interval (CI): An interval constructed so that a statement that the true
value of an unknown parameter lies in this interval will be true, in the long run, a
proportion (95%) of the time that the statement is made.
Marijuana: A form of cannabis that can be smoked.
Odds ratio: The “odds ratio” is a measure of association between a condition and a
possible risk factor. An odds ratio around 1.0 suggests no association; an odds ratio of
<1.0 suggests an association that is beneficial; and an odds ratio of >1.0 suggests a
harmful association. The size of an odds ratio is an important factor in judging whether
an association may indicate a causal relationship. For example, the odds ratio linking
smoking and lung cancer is about 20 (representing a 20-fold increase in the likelihood
of smokers developing lung cancer). An odds ratio of this size indicates that smoking
plays a crucial, though not necessarily the only, role in causing lung cancer The odds
ratio for developing schizophrenia in someone with a first degree relative with the
condition – compared to someone who has not – is about 10 (in the absence of
cannabis use). In this instance, the size of the odds ratio again strongly suggests a
causal role for genetic factors.
Potency: The content of the major active compound r9-tetrahydrocannabinol (THC).
Psychotic illness: To meet the criteria for a “psychotic illness”, the symptoms
described below generally need to meet a threshold of severity, last for a significant
period of time, and have an adverse impact on the person’s social functioning
Psychotic symptoms: Disordered thinking, delusions (abnormal beliefs) and
hallucinations (abnormal perceptual experiences).
Risk factor: A determinant of ill-health that increases the probability of developing a
certain disease.
Schizophrenia: A severe mental disorder characterised by delusions, hallucinations,
incoherence and physical agitation
Sinsemilla: Meaning: “without seeds”. The highest potency herbal cannabis,
representing the flowering tops of unfertilised female cannabis plants. Sinsemilla is
normally produced by intensive indoor cultivation techniques which may include use of
selected seed varieties, hydroponic cultivation, additional lighting and artificial control
of “day” length. It is both home-grown and imported, although much is now grown in
the UK.
Skunk: A form of sinsemilla with a characteristic odour. It is often of high potency.
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Tetrahydrocannabinol: The main psychoactive component of cannabis products
mimicking several naturally-occurring substances known as endocannabinoids.
Traditional, imported herbal cannabis: A dried plant preparation of floral and foliar
material imported from the Caribbean, Africa or Asia.
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